I Westermann de Patiño

Learn More
SETTING Randomised Phase IIB clinical trial. OBJECTIVES To assess whether increasing the dose of rifampicin (RMP) from 10 mg/kg to 15 or 20 mg/kg results in an increase in grade 3 or 4 hepatic adverse events and/or serious adverse events (SAE). METHODS Three hundred human immunodeficiency virus negative patients with newly diagnosed microscopy-positive(More)
  • 1